Earning Analysis
Welcome to our in-depth analysis of Royalty Pharma PLC(RPRX) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Royalty Pharma PLC earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-05 | Pre-Market | 1.11 | 1.17 | +5.41 | 763.51M | 814.00M | +6.61 | +6.82 | +1.85 |
| FY2025Q2 | 2025-08-06 | Pre-Market | 1.10 | 1.14 | +3.64 | 693.74M | 727.00M | +4.80 | -2.08 | -4.54 |
| FY2025Q1 | 2025-05-08 | Pre-Market | 0.99 | 1.06 | +7.07 | 724.69M | 568.00M | -21.62 | +1.07 | +0.21 |
| FY2024Q4 | 2025-02-11 | Pre-Market | 1.09 | 1.15 | +5.50 | 743.60M | 594.00M | -20.12 | +1.67 | +3.56 |
| FY2024Q2 | 2024-08-08 | Pre-Market | 0.95 | 0.96 | +1.21 | 645.29M | 537.00M | -16.78 | -4.04 | -2.20 |
| FY2024Q1 | 2024-05-09 | - | 0.96 | 0.98 | +2.08 | 709.45M | 568.00M | -19.94 | -0.07 | +0.79 |
| FY2023Q4 | 2024-02-15 | - | 1.03 | 1.15 | +11.65 | 674.54M | 596.00M | -11.64 | +3.23 | +6.63 |
| FY2023Q3 | 2023-11-08 | - | 0.81 | 0.79 | -2.47 | 618.49M | 536.31M | -13.29 | +0.25 | -0.11 |
| FY2023Q2 | 2023-08-08 | - | 0.83 | 0.85 | +2.41 | 536.59M | 538.00M | +0.26 | -0.88 | -2.30 |
| - | 2023-05-09 | - | 1.32 | 1.60 | +21.21 | - | - | - | -4.31 | -3.35 |
RPRX Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Royalty Pharma PLC reported performance for FY2025Q3, announced on 2025-11-05. The company achieved an EPS of 1.17, compared to analyst estimates of 1.11 by 5.41% . Revenue for the quarter reached 814.00M compared to expectations of 763.51M by 6.61% .
The stock price reacted with a 6.82% one-day change and a 1.85% five-day change following the earnings release. These movements reflect market reaction in Royalty Pharma PLC growth trajectory and strategic initiatives.
RPRX Earnings Forecast
Looking ahead, Royalty Pharma PLC(RPRX) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 829.22M and an EPS of 1.31.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.68%, while EPS estimates have been Revise Upward by 3.43%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 3.42% . These revisions correlate with a 8.54% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Royalty Pharma PLC long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between RPRX's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+0.68%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+3.43%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+3.42%
In Past 3 Month
Stock Price
Go Up
+8.54%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:3.17B
--
EPS Estimate-Annual FY 2025:4.63
—
Stock Price39.15
RPRX Revenue and EPS Performance: A Historical Perspective
Royalty Pharma PLC revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-05,Pre-Market):
EPS: 1.17 (Actual) vs.1.11 (Estimate) (5.41%)
Revenue: 814.00M (Actual) vs. 763.51M (Estimate) (6.61%)
Price Reaction: 6.82%(1-Day), 1.85%(5-Day)
FY2025Q2 (2025-08-06,Pre-Market):
EPS: 1.14 (Actual) vs.1.10 (Estimate) (3.64%)
Revenue: 727.00M (Actual) vs. 693.74M (Estimate) (4.80%)
Price Reaction: -2.08%(1-Day), -4.54%(5-Day)
FY2025Q1 (2025-05-08,Pre-Market):
EPS: 1.06 (Actual) vs.0.99 (Estimate) (7.07%)
Revenue: 568.00M (Actual) vs. 724.69M (Estimate) (-21.62%)
Price Reaction: 1.07%(1-Day), 0.21%(5-Day)
Earnings Reaction
The chart below shows how RPRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RPRX sees a -0.17% change in stock price 10 days leading up to the earnings, and a -1.09% change 10 days following the report. On the earnings day itself, the stock moves by -0.21%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 0.89% on the day following the earnings release and then changed by -4.38% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Royalty Pharma PLC (RPRX) Q3 2025 Earnings Call Summary
Positive
2025-11-05
The earnings call summary indicates strong financial performance with a reduction in operating costs and high cash flow margins. The company is actively returning capital to shareholders through significant share repurchases. The Q&A section reveals management's confidence in their strategic initiatives, despite some unclear responses. The guidance suggests growth and cost efficiency improvements. Although the market cap is unavailable, the positive aspects outweigh the negatives, predicting a 2% to 8% stock price increase over the next two weeks.
Royalty Pharma PLC (RPRX) Q2 2025 Earnings Call Summary
Positive
2025-08-06
The earnings call summary shows strong financial performance with high cash flow and a robust share repurchase plan. Positive clinical updates and raised financial guidance further boost sentiment. The Q&A section reveals optimism about deal capacity and market opportunities, especially in China and pancreatic cancer. Despite some uncertainties like the Vertex royalties dispute, the overall positive outlook and strategic initiatives suggest a likely stock price increase of 2% to 8% over the next two weeks.
Royalty Pharma PLC (RPRX) Q1 2025 Earnings Call Summary
Positive
2025-05-08
The earnings call reveals strong financial performance with 13% growth in royalty receipts, a robust share repurchase plan, and optimistic financial guidance. Despite high debt, the company shows effective cash management and shareholder returns. The Q&A section addresses potential risks, but management remains confident about minimal impact from tariffs and policy uncertainties. Overall, the positive financial metrics and strategic initiatives outweigh concerns, suggesting a positive stock price movement.
Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Summary
Positive
2025-02-11
The earnings call summary presents several positive factors: strong financial performance with a 13% growth in portfolio receipts, successful capital deployment, and a substantial share repurchase program. The raised guidance and positive outlook on synthetic royalties further enhance the sentiment. Despite some uncertainties in the Q&A, such as unclear management responses and interest rate risks, the overall sentiment is positive due to record high revenue, increased shareholder returns, and optimistic future guidance.
Royalty Pharma plc (RPRX) Q3 2024 Earnings Call Summary
Positive
2024-11-06
The earnings call summary indicates strong financial performance, with 15% YoY growth in both Portfolio and Royalty Receipts, and raised guidance for 2024. The share repurchase program and high adjusted EBITDA margin further support positive sentiment. However, regulatory risks, competition, and significant debt are concerns. The Q&A section shows optimism in product launches and investment strategy, despite some unclear management responses. Overall, the positive financial metrics and strategic initiatives outweigh the risks, suggesting a positive stock price movement.
Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Summary
Positive
2024-08-08
The earnings call highlights strong financial performance with 12% growth in Portfolio Receipts and 11% growth in Royalty Receipts. The company has a solid shareholder return strategy with a significant share buyback program and dividend growth commitment. Despite concerns about supply chain and financial leverage, the optimistic guidance and strong cash flow provide a positive outlook. The Q&A section reveals confidence in future opportunities and investments, with management indicating potential growth in royalties. Overall, the sentiment is positive, with a likely stock price increase in the 2% to 8% range over the next two weeks.
People Also Watch
FAQ
What were the key highlights of RPRX’s latest earnings report for FY2025Q3?
How did RPRX’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for RPRX for 2025/Q4?
How does RPRX’s stock price correlate with earnings forecast revisions?
What should investors expect from RPRX’s next earnings report?